Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8641181 | 1.00 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL30052811 | 1.00 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL935682 | 1.00 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL30051556 | 0.93 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL30051030 | 0.90 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL15756642 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL29155527 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL8014043 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL29155528 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL8014033 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CA2CA1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709912-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BioAtla, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4554968-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | Centessa Pharmaceuticals (UK) Limited (GB) | 2025-05-21 | — | — | EP | claimed |
| CN-119080883-A | Antibacterial peptide and application thereof | 合肥科生景肽生物科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| WO-2024232976-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| US-20240360175-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | OXFORD FINANCE LLC | 2024-10-31 | — | — | US | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4424365-A2 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4017281-B1 | PET FOOD COMPOSITIONS | HILLS PET NUTRITION INC (US) | 2024-08-28 | — | — | EP | claimed |
| US-20090170786-A1 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2009-07-02 | — | — | US | claimed |
| US-20090105123-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2009-04-23 | — | — | US | claimed |
| CN-101316582-A | Method of treating muscle loss | NESTEC SA (CH) | 2008-12-03 | — | — | CN | claimed |
| EP-1957061-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2008-08-20 | — | — | EP | claimed |
| EP-1940252-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2008-07-09 | — | — | EP | claimed |
| WO-2007064618-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2007-06-07 | — | — | WO | claimed |
| WO-2007053390-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2007-05-10 | — | — | WO | claimed |
| US-6429220-B1 | COMPRISES AN ISOTHIAZOLONE COMPOUND AND AN AMINOCARBOXYLIC ACID | KURITA WATER INDUSTRIES LTD. (JP) | 2002-08-06 | — | — | US | claimed |
| EP-0512435-B1 | Method of crystallizing aspartame | AJINOMOTO KK (JP) | 1997-01-22 | — | — | EP | claimed |
| US-5298648-A | Method of crystallizing aspartame | AJINOMOTO CO., INC. (JP) | 1994-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360175-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 4426/4885L3MBTL1 78/4885CA2 2217/4885 |
| US-20090105123-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | BCAT2, CPT1B, BCAT1 | ALDH1A1 3467/4885L3MBTL1 354/4885CA2 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.